RECRUITING

Development of Patient-Reported Outcome Measures Assessing Tumor-Related Disfigurement and Appearance Concerns in Neurofibromatosis Type 1

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Background: Neurofibromatosis 1 (NF1) is a disease that causes tumors to grow along the nerves. These include plexiform neurofibromas (pNF) and cutaneous neurofibromas (cNF). Both pNF and cNF can be visible to other people. These tumors can affect a person s appearance and quality of life. Researchers want to be able to assess changes in appearance before and after treatment for NF1 tumors. Objective: To see if two questionnaires can help assess people s ratings about the appearance of their pNF and cNF tumors. Eligibility: People aged 8 years and older with pNF and people 12 years and older either with cNF or both pNF and cNF. Adult caregivers of children with pNF and cNF are also needed. Design: Participants will complete questionnaires on paper or by phone, computer, or tablet. They will answer questions about how they look, how they feel, and how they feel about the way they look. Participants will meet in at least 1 remote focus group or individual interview. The meeting will last about 1 hour. Each group will include 3 to 5 people, organized by age: 8 to 11 years, 12 to 17 years, 18 to 29 years, and over 30 years. Adult caregivers will meet in a group with other caregivers. They will discuss their NF1 symptoms; how their tumors look; how they feel about the way their tumors look; and their daily activities. They will give their opinions about 2 questionnaires about appearance. The group and individual meetings will be audio-recorded and transcribed. Information that can reveal individual identities will be removed.

Official Title

Development of Patient-Reported Outcome Measures Assessing Tumor-Related Disfigurement and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study

Quick Facts

Study Start:2025-04-10
Study Completion:2027-03-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06880991

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:5 Years to 120 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participants must self-report a diagnosis of NF1 OR be the caregiver of a child with NF1 (5-17 years old with \[pNF\] or 12-17 years old child with \[cNF\])
  2. * Participants with NF1 must self-report a pNF and/or cNF tumor(s) that is visible to that individual OR others
  3. * Caregivers of a child with NF1 must report a pNF and/or cNF tumor(s) that the child has that is visible to the child OR others
  4. * Age requirements:
  5. * \>= 8 years old (participants with pNF)
  6. * \>= 12 years old (participants with cNF)
  7. * \>= 12 years old (participants with pNF and cNF)
  8. * \>= 18 years (caregivers only)
  9. * Access to device with internet
  10. * Ability to understand English and comfort discussing their medical condition in English
  11. * The ability of adult participant or caregiver of minor participants to understand and the willingness to sign a written informed consent document
  1. * Physical or cognitive limitations that would prevent them from being able to participate in a focus group or interview, or unwillingness to do so
  2. * If saturation has been met within a particular age group, potential participants from that completed age group will no longer be eligible.

Contacts and Locations

Study Contact

Staci M Peron, Ph.D.
CONTACT
(240) 760-6025
martins@mail.nih.gov

Principal Investigator

Staci M Peron, Ph.D.
PRINCIPAL_INVESTIGATOR
National Cancer Institute (NCI)

Study Locations (Sites)

National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
United States

Collaborators and Investigators

Sponsor: National Cancer Institute (NCI)

  • Staci M Peron, Ph.D., PRINCIPAL_INVESTIGATOR, National Cancer Institute (NCI)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-04-10
Study Completion Date2027-03-31

Study Record Updates

Study Start Date2025-04-10
Study Completion Date2027-03-31

Terms related to this study

Keywords Provided by Researchers

  • Qualitative
  • Focus Groups
  • Instrument Development

Additional Relevant MeSH Terms

  • Neurofibromatosis Type 1
  • Neurofibroma